Adaptive Bayesian Design for Phase I Dose-Finding Trials Using a Joint Model of Response and Toxicity

REFERENCES

• Babb , J. , Rogatko , A. , Zacks , S. ( 1997 ). Cancer phase I clinical trials: efficient dose escalation with overdose control . Statistics in Medicine 11 : 1103 – 1120 .
   Google Scholar
• Bekele , B. , Shen , Y. ( 2005 ). A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial . Biometrics 61 : 344 – 354 .
   Web of Science ®Google Scholar
• Braun , T. ( 2002 ). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes . Controlled Clinical Trials 23 : 240 – 256 .
   PubMedGoogle Scholar
• Bryant , J. , Day , R. ( 1995 ). Incorporating toxicity considerations into the design of two-stage phase II clinical trials . Biometrics 51 : 1372 – 1383 .
   PubMed Web of Science ®Google Scholar
• Dragalin , V. , Fedorov , V. ( 2006 ). Adaptive designs for dose-finding based on efficacy toxicity response . Journal of Statistical Planning and Inference 136 ( 6 ): 1800 – 1823 .
   Web of Science ®Google Scholar
• Dragalin , V. , Fedorov , V. , Wu , Y. ( 2008 ). Two-stage design for dose-finding that accounts for both efficacy and safety . Statistics in Medicine 27 ( 25 ): 5156 – 5176 .
   PubMed Web of Science ®Google Scholar
• Druker , B. , Talpaz , M. , Resta , D. , Peng , B. , Buchdunger , E. , Ford , J. M. , Lydon , N. B. , Kantarjian , H. , Capdeville , R. , Ohno-Jones , S. , Sawyers , C. L. ( 2001 ). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia . The New England Journal of Medicine 344 ( 14 ): 1031 – 1037 .
   PubMed Web of Science ®Google Scholar
• Druker , B. J. , Guilhot , F. , O'Brien , S. G. , Gathmann , I. , Kantarjian , H. , Gattermann , N. , Deininger , M. W. , Silver , R. T. , Goldman , J. M. , Stone , R. M. , Cervantes , F. , Hochhaus , A. , Powell , B. L. , Gabrilove , J. L. , Rousselot , P. , Reiffers , J. , Cornelissen , J. J. , Hughes , T. , Agis , H. , Fischer , T. , Verhoef , G. , Shepherd , J. , Saglio , G. , Gratwohl , A. , Nielsen , J. L. , Radich , J. P. , Simonsson , B. , Taylor , K. , Baccarani , M. , So , C. , Letvak , L. , Larson , R. A. ( 2006 ). IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia . New England Journal of Medicine 355 ( 23 ): 2408 – 2417 .
   PubMed Web of Science ®Google Scholar
• Durham , S. , Flournoy , N. , Rosenberger , W. ( 1997 ). A random walk rule for phase I clinical trials . Biometrics 53 : 745 – 760 .
   PubMed Web of Science ®Google Scholar
• Evans , W. , Horner , M. , Chu , Y. , Kalwinsky , D. , Roberts , W. ( 1991 ). Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia . Journal of Pediatrics 119 : 985 – 989 .
   PubMed Web of Science ®Google Scholar
• Gasparini , M. , Eisele , J. (2000). A curve-free method for phase I clinical trials. Biometrics 56:609–615.
   PubMed Web of Science ®Google Scholar
• Goodman , S. , Zahurak , M. , Piantadosi , S. ( 1995 ). Some practical improvments in the continual reassessment method for phase I studies . Statistics in Medicine 14 : 1149 – 1161 .
   PubMed Web of Science ®Google Scholar
• Gooley , T. , Martin , P. , Fisher , L. , Pettinger , M. ( 1994 ). Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation . Controlled Clinical trials 15 : 450 – 462 .
   PubMedGoogle Scholar
• Haines , L. , Perevoszkaya , I. , Rosenberger , W. ( 2003 ). Bayesian optimal designs for phase I clinical trials . Biometrics 59 : 591 – 600 .
   PubMed Web of Science ®Google Scholar
• Ivanova , A. , Montazer-Haghighi , A. , Mohanty , S. , Durham , S. ( 2003 ). Improved up-and-down designs for phase I trials . Statistics in Medicine 22 : 69 – 82 .
   PubMed Web of Science ®Google Scholar
• Korn , E. , Midthune , D. , Chen , T. , Rubinstein , L. , Christian , M. , Simon , R. ( 1994 ). A comparison of two phase I designs . Statistics in Medicine 13 : 1799 – 1806 .
   PubMed Web of Science ®Google Scholar
• Lennard , L. , Lewis , I. , Michelagnoli , M. , Lilleyman , J. ( 1997 ). Thiopurine methyltransferase deficiency in childhood lymphoblastic leukemia: 6-mercaptopurine dosage strategies . Medical and Pediatric Oncology 29 : 252 – 255 .
   PubMedGoogle Scholar
• Leung , D. , Wang , Y. ( 2001 ). Isotonic designs for phase I trials . Controlled Clinical Trials 22 : 126 – 138 .
   PubMedGoogle Scholar
• Loke , Y. , Tan , S. , Cai , Y. , Machin , D. ( 2006 ). A Bayesian dose finding design for dual endpoint phase I trials . Statistics in Medicine 25 : 3 – 22 .
   PubMed Web of Science ®Google Scholar
• Moller , S. ( 1995 ). An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses . Statistics in Medicine 14 : 911 – 922 .
   PubMed Web of Science ®Google Scholar
• O'Quigley , J. , Shen , L. Z. ( 1996 ). Continual reassessment method: a likelihood approach . Biometrics 52 : 673 – 684 .
   PubMed Web of Science ®Google Scholar
• O'Quigley , J. , Pepe , M. , Fisher , M. ( 1990 ). Continual reassessment method: a practical design for phase I clinical trials in cancer . Biometrics 46 : 33 – 48 .
   PubMed Web of Science ®Google Scholar
• O'Quigley , J. , Hughes , M. , Fenton , T. ( 2001 ). Dose-finding designs for HIV studies . Biometrics 57 : 1018 – 1029 .
   PubMed Web of Science ®Google Scholar
• Potter , D. ( 2002 ). Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer . Statistics in Medicine 21 : 1805 – 1823 .
   PubMed Web of Science ®Google Scholar
• Relling , M. , Dervieux , T. ( 2001 ). Pharmacogenetics and cancer therapy . Nature Reviews Cancer 1 : 99 – 108 .
   PubMed Web of Science ®Google Scholar
• Relling , M. , Hancock , M. , Rivera , G. , Sundlund , J. , Ribeiro , R. , Krynetski , E. , Pui , C. H. , Evans , W. ( 1999 ). Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus . Journal of the National Cancer Institute 91 : 2001 – 2008 .
   PubMed Web of Science ®Google Scholar
• Rogatko , A. , Schoeneck , D. , Jonas , W. , Tighiouart , M. , Khuri , F. R. , Porter , A. ( 2007 ). Translation of innovative designs into phase I trials . Journal of Clinical Oncology 25 ( 31 ): 4982 – 4986 .
   PubMed Web of Science ®Google Scholar
• Simon , R. , Freidlin , B. , Rubinstein , L. , Arbuck , S. , Collins , J. , Christian , M. ( 1997 ). Accelerated titration designs for phase I clinical trials in oncology . Journal of the National Cancer Institute 89 : 1138 – 1147 .
   PubMed Web of Science ®Google Scholar
• Stallard , N. ( 2003 ). Decision-theoretic design for phase II clinical trials allowing for competing studies . Biometrics 59 : 402 – 409 .
   PubMed Web of Science ®Google Scholar
• Storer , B. ( 1989 ). Design and analysis of phase I clinical trials . Biometrics 45 : 925 – 937 .
   PubMed Web of Science ®Google Scholar
• Thall , P. , Russell , K. ( 1998 ). A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials . Biometrics 54 : 251 – 264 .
   PubMed Web of Science ®Google Scholar
• Thall , P. , Estey , E. , Sung , H. (1999). A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Investigational New Drugs 17:155–167.
   PubMed Web of Science ®Google Scholar
• Thall , P. , Cook , J. ( 2004 ). Dose-finding based on efficacy-toxicity trade-offs . Biometrics 60 : 684 – 693 .
   PubMed Web of Science ®Google Scholar
• Whitehead , J. , Brunier , H. ( 1995 ). Bayesian decision procedures for dose determing experiments . Statistics in Medicine 14 : 885 – 893 .
   PubMed Web of Science ®Google Scholar
• Zhou , Y. , Whitehead , J. , Bonvini , E. , Stevens , J. ( 2006 ). Bayesian decision procedures for binary and continuous bivariate dose-escalation studies . Pharmaceutical Statistics 5 : 125 – 133 .
   PubMed Web of Science ®Google Scholar